LifeTech Scientific Management
Management criteria checks 2/4
LifeTech Scientific's CEO is Yuehui Xie, appointed in Mar 2015, has a tenure of 9.75 years. total yearly compensation is CN¥8.39M, comprised of 39.9% salary and 60.1% bonuses, including company stock and options. directly owns 15.41% of the company’s shares, worth HK$1.04B. The average tenure of the management team and the board of directors is 9.8 years and 10.7 years respectively.
Key information
Yuehui Xie
Chief executive officer
CN¥8.4m
Total compensation
| CEO salary percentage | 39.9% |
| CEO tenure | 9.8yrs |
| CEO ownership | 15.4% |
| Management average tenure | 9.8yrs |
| Board average tenure | 10.7yrs |
Recent management updates
Recent updates
LifeTech Scientific Corporation (HKG:1302) Looks Just Right With A 29% Price Jump
Oct 02
Some Confidence Is Lacking In LifeTech Scientific Corporation's (HKG:1302) P/E
Jul 05LifeTech Scientific's (HKG:1302) Soft Earnings Are Actually Better Than They Appear
Apr 25What LifeTech Scientific Corporation's (HKG:1302) P/E Is Not Telling You
Dec 25Returns On Capital At LifeTech Scientific (HKG:1302) Have Stalled
Nov 28At HK$2.37, Is LifeTech Scientific Corporation (HKG:1302) Worth Looking At Closely?
Nov 03Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)
Aug 17Is There Now An Opportunity In LifeTech Scientific Corporation (HKG:1302)?
Jul 18Investors Met With Slowing Returns on Capital At LifeTech Scientific (HKG:1302)
May 05Here's What To Make Of LifeTech Scientific's (HKG:1302) Decelerating Rates Of Return
Oct 14There's Been No Shortage Of Growth Recently For LifeTech Scientific's (HKG:1302) Returns On Capital
Jul 15Does LifeTech Scientific (HKG:1302) Deserve A Spot On Your Watchlist?
Jun 30A Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)
Jun 15Returns At LifeTech Scientific (HKG:1302) Are On The Way Up
Apr 03Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock
Mar 15Is LifeTech Scientific Corporation (HKG:1302) Potentially Undervalued?
Jan 22Some Investors May Be Worried About LifeTech Scientific's (HKG:1302) Returns On Capital
Dec 19Here's Why I Think LifeTech Scientific (HKG:1302) Might Deserve Your Attention Today
Dec 06Is LifeTech Scientific (HKG:1302) A Risky Investment?
Nov 20An Intrinsic Calculation For LifeTech Scientific Corporation (HKG:1302) Suggests It's 34% Undervalued
Oct 12The Returns On Capital At LifeTech Scientific (HKG:1302) Don't Inspire Confidence
Sep 13Should You Be Adding LifeTech Scientific (HKG:1302) To Your Watchlist Today?
Aug 28What Is LifeTech Scientific Corporation's (HKG:1302) Share Price Doing?
Aug 13LifeTech Scientific's (HKG:1302) Returns On Capital Not Reflecting Well On The Business
Jun 08Here's Why I Think LifeTech Scientific (HKG:1302) Is An Interesting Stock
May 26Should You Investigate LifeTech Scientific Corporation (HKG:1302) At HK$4.14?
May 11LifeTech Scientific (HKG:1302) Could Easily Take On More Debt
Mar 31Shareholders Are Thrilled That The LifeTech Scientific (HKG:1302) Share Price Increased 274%
Feb 21Do Insiders Own Lots Of Shares In LifeTech Scientific Corporation (HKG:1302)?
Jan 26Does LifeTech Scientific's (HKG:1302) Statutory Profit Adequately Reflect Its Underlying Profit?
Dec 13
Are Strong Financial Prospects The Force That Is Driving The Momentum In LifeTech Scientific Corporation's HKG:1302) Stock?
Nov 25CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CN¥249m |
| Mar 31 2024 | n/a | n/a | CN¥256m |
| Dec 31 2023 | CN¥8m | CN¥3m | CN¥263m |
| Sep 30 2023 | n/a | n/a | CN¥297m |
| Jun 30 2023 | n/a | n/a | CN¥331m |
| Mar 31 2023 | n/a | n/a | CN¥328m |
| Dec 31 2022 | CN¥6m | CN¥2m | CN¥325m |
| Sep 30 2022 | n/a | n/a | CN¥314m |
| Jun 30 2022 | n/a | n/a | CN¥303m |
| Mar 31 2022 | n/a | n/a | CN¥298m |
| Dec 31 2021 | CN¥14m | CN¥2m | CN¥292m |
| Sep 30 2021 | n/a | n/a | CN¥307m |
| Jun 30 2021 | n/a | n/a | CN¥322m |
| Mar 31 2021 | n/a | n/a | CN¥269m |
| Dec 31 2020 | CN¥5m | CN¥2m | CN¥216m |
| Sep 30 2020 | n/a | n/a | CN¥176m |
| Jun 30 2020 | n/a | n/a | CN¥136m |
| Mar 31 2020 | n/a | n/a | CN¥132m |
| Dec 31 2019 | CN¥16m | CN¥2m | CN¥129m |
| Sep 30 2019 | n/a | n/a | CN¥138m |
| Jun 30 2019 | n/a | n/a | CN¥146m |
| Mar 31 2019 | n/a | n/a | CN¥134m |
| Dec 31 2018 | CN¥14m | CN¥1m | CN¥121m |
| Sep 30 2018 | n/a | n/a | CN¥134m |
| Jun 30 2018 | n/a | n/a | CN¥147m |
| Mar 31 2018 | n/a | n/a | CN¥155m |
| Dec 31 2017 | CN¥3m | CN¥1m | CN¥163m |
Compensation vs Market: Yuehui's total compensation ($USD1.15M) is above average for companies of similar size in the Hong Kong market ($USD478.94K).
Compensation vs Earnings: Yuehui's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Yuehui Xie (55 yo)
9.8yrs
Tenure
CN¥8,392,000
Compensation
Mr. Yuehui Xie has been the Chief Executive Officer at LifeTech Scientific Corporation since March 2, 2015. Mr. Xie is responsible for overall strategic planning and management of LifeTech Scientific Corpo...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 9.8yrs | CN¥8.39m | 15.41% HK$ 1.0b | |
| CFO, Executive VP | 13.2yrs | CN¥6.85m | 0.54% HK$ 36.4m | |
| Executive Director | no data | no data | no data |
9.8yrs
Average Tenure
53yo
Average Age
Experienced Management: 1302's management team is seasoned and experienced (9.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 18.3yrs | CN¥8.39m | 15.41% HK$ 1.0b | |
| CFO, Executive VP | 9.8yrs | CN¥6.85m | 0.54% HK$ 36.4m | |
| Executive Director | no data | no data | no data | |
| Independent Non-Executive Director | 13.2yrs | CN¥180.00k | no data | |
| Independent Non-Executive Director | 10.7yrs | CN¥180.00k | no data | |
| Non-Executive Director | 10.7yrs | CN¥180.00k | no data | |
| Independent Non-Executive Director | 8.9yrs | CN¥180.00k | no data |
10.7yrs
Average Tenure
55yo
Average Age
Experienced Board: 1302's board of directors are seasoned and experienced ( 10.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 07:01 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
LifeTech Scientific Corporation is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Chak Yuen | BOCI Research Ltd. |
| Yuan Gao | China International Capital Corporation Limited |
| Hanqing Zhu | Guosen Securities Co., Ltd. |